secwatch.observer — SEC 8-K summary
======================================

Issuer:     Scholar Rock Holding Corp (SRRK)
CIK:        0001727196
Form:       8-K
Filed at:   2023-08-09T23:59:59+00:00
Accession:  0001157523-23-001305
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Scholar Rock Q2 net loss $37.9M; cash $249M; SAPPHIRE enrollment on track for Q3 2023
--------------------------------------------------------------------------------

- Net loss $37.9M in Q2 2023 vs $44.0M in Q2 2022; no revenue for either period.
- Cash, equivalents & marketable securities $249M as of Jun 30, 2023; expected to fund into 2025.
- Phase 3 SAPPHIRE trial enrollment completion expected Q3 2023; top-line data in 2H 2024.
- 36-month extension data from Phase 2 TOPAZ showed substantial sustained motor function improvement.
- Clinical & biomarker update from DRAGON Part B (SRK-181) anticipated in 2H 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1727196/000115752323001305/0001157523-23-001305-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1727196/000115752323001305/a53519737.htm
  HTML page:      https://secwatch.observer/filing/0001157523-23-001305

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer